DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
PF-06291874
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Glucagon receptor antagonist
PF-06291874
×
Maximum Phase:
2
First Approval:
None
UNII:
CGY4I8F278
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-863233
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cell division cycle 7-related protein kinase inhibitor
BMS-863233
×
Maximum Phase:
2
First Approval:
None
UNII:
8QK62S7492
Molecule Type:
Small molecule
Molecular Formula:
C14H12ClN3O2
Molecular Weight:
289.72
AlogP:
2.75
PSA:
70.92
HBD:
2.0
HBA:
#RotB:
1.0
Source:
NBI-921352
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NBI-921352
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H25FN4O2S2
Molecular Weight:
460.6
AlogP:
4.1
PSA:
65.54
HBD:
1.0
HBA:
#RotB:
7.0
Source:
ATX08-001
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus; Neuralgia, Postherpetic
Peroxisome proliferator-activated receptor gamma modulator
ATX08-001
×
Maximum Phase:
2
First Approval:
None
UNII:
V5Q32BZX79
Molecule Type:
Small molecule
Molecular Formula:
C21H23Cl2N3O3S
Molecular Weight:
468.41
AlogP:
4.95
PSA:
81.06
HBD:
1.0
HBA:
#RotB:
8.0
Source:
AR9281
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Epoxide hydratase inhibitor
AR9281
×
Maximum Phase:
2
First Approval:
None
UNII:
4HA03Q8EZ9
Molecule Type:
Small molecule
Molecular Formula:
C18H29N3O2
Molecular Weight:
319.45
AlogP:
2.27
PSA:
61.44
HBD:
2.0
HBA:
#RotB:
2.0
Source:
PIBOSEROD
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation; Heart Failure
Serotonin 4 (5-HT4) receptor antagonist
PIBOSEROD
×
Maximum Phase:
2
First Approval:
None
UNII:
4UQ3S81B25
Molecule Type:
Small molecule
Molecular Formula:
C22H31N3O2
Molecular Weight:
369.51
AlogP:
3.67
PSA:
46.5
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PF-00217830
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Dopamine D2 receptor partial agonist
PF-00217830
×
Maximum Phase:
2
First Approval:
None
UNII:
8BC08N1MS5
Molecule Type:
Small molecule
Molecular Formula:
C26H30N4O2
Molecular Weight:
430.55
AlogP:
4.1
PSA:
57.7
HBD:
1.0
HBA:
#RotB:
7.0
Source:
QUERCETIN-3'-O-PHOSPHATE
2
Small molecule
Investigational
Unknown
Unknown
Glucose Intolerance
Unknown
QUERCETIN-3'-O-PHOSPHATE
×
Maximum Phase:
2
First Approval:
None
UNII:
E2I4458LJN
Molecule Type:
Small molecule
Molecular Formula:
C15H11O10P
Molecular Weight:
382.22
AlogP:
1.75
PSA:
177.89
HBD:
6.0
HBA:
#RotB:
3.0
Source:
NAFITHROMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Pneumonia, Bacterial
Unknown
NAFITHROMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
75F74Y2R70
Molecule Type:
Small molecule
Molecular Formula:
C42H62N6O11S
Molecular Weight:
859.06
AlogP:
4.12
PSA:
224.18
HBD:
2.0
HBA:
#RotB:
10.0
Source:
NAMODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C, Chronic; Carcinoma, Hepatocellular; Non-alcoholic Fatty Liver Disease
Adenosine A3 receptor agonist
NAMODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
Z07JR07J6C
Molecule Type:
Small molecule
Molecular Formula:
C18H18ClIN6O4
Molecular Weight:
544.74
AlogP:
1.06
PSA:
134.42
HBD:
4.0
HBA:
#RotB:
5.0
Source:
ELISMETREP
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Hot Flashes
Transient receptor potential cation channel subfamily M member 8 inhibitor
ELISMETREP
×
Maximum Phase:
2
First Approval:
None
UNII:
KIB8V5UR7D
Molecule Type:
Small molecule
Molecular Formula:
C27H21F3N2O5S
Molecular Weight:
542.53
AlogP:
6.1
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
8.0
Source:
ANABASEINE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Unknown
ANABASEINE
×
Maximum Phase:
2
First Approval:
None
UNII:
DYE103K23I
Molecule Type:
Small molecule
Molecular Formula:
C10H12N2
Molecular Weight:
160.22
AlogP:
2.05
PSA:
25.25
HBD:
0.0
HBA:
#RotB:
1.0
Source:
UBENIMEX
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary; Lymphedema
Unknown
UBENIMEX
×
Maximum Phase:
2
First Approval:
None
UNII:
I0J33N5627
Molecule Type:
Small molecule
Molecular Formula:
C16H24N2O4
Molecular Weight:
308.38
AlogP:
0.53
PSA:
112.65
HBD:
4.0
HBA:
#RotB:
8.0
Source:
FIRTECAN PEGOL
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Neoplasms; Breast Neoplasms
Unknown
FIRTECAN PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
WC4978T687
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGB-BP-3
2
Small molecule
Investigational
Unknown
Unknown
Clostridium Infections
DNA binding agent
MGB-BP-3
×
Maximum Phase:
2
First Approval:
None
UNII:
532PWU9738
Molecule Type:
Small molecule
Molecular Formula:
C36H37N7O4
Molecular Weight:
631.74
AlogP:
4.65
PSA:
122.52
HBD:
3.0
HBA:
#RotB:
10.0
Source:
TALAROZOLE
2
Small molecule
Investigational
Unknown
Unknown
Inflammation; Acne Vulgaris; Psoriasis
Cytochrome P450 26A1 inhibitor
TALAROZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
XKD9N5CJ6W
Molecule Type:
Small molecule
Molecular Formula:
C21H23N5S
Molecular Weight:
377.52
AlogP:
5.66
PSA:
55.63
HBD:
1.0
HBA:
#RotB:
7.0
Source:
NEOANDROGRAPHOLIDE
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis, Chronic Progressive; Colorectal Neoplasms
Unknown
NEOANDROGRAPHOLIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
XBY0Z806J2
Molecule Type:
Small molecule
Molecular Formula:
C26H40O8
Molecular Weight:
480.6
AlogP:
1.85
PSA:
125.68
HBD:
4.0
HBA:
#RotB:
7.0
Source:
GALICAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Cystic fibrosis transmembrane conductance regulator positive modulator
GALICAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
J0IIT8QSQS
Molecule Type:
Small molecule
Molecular Formula:
C28H21F4NO7
Molecular Weight:
559.47
AlogP:
5.72
PSA:
103.32
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BREQUINAR
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Severe Acute Respiratory Syndrome
Unknown
BREQUINAR
×
Maximum Phase:
2
First Approval:
None
UNII:
5XL19F49H6
Molecule Type:
Small molecule
Molecular Formula:
C23H15F2NO2
Molecular Weight:
375.37
AlogP:
5.85
PSA:
50.19
HBD:
1.0
HBA:
#RotB:
3.0
Source:
L-THREONIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
L-THREONIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
75B0PMW2JF
Molecule Type:
Small molecule
Molecular Formula:
C4H8O5
Molecular Weight:
136.1
AlogP:
-2.21
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
3.0
Source:
SAMIDORPHAN
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Alcoholism; Feeding and Eating Disorders; Schizophrenia
Mu opioid receptor antagonist
SAMIDORPHAN
×
Maximum Phase:
2
First Approval:
None
UNII:
7W2581Z5L8
Molecule Type:
Small molecule
Molecular Formula:
C21H26N2O4
Molecular Weight:
370.45
AlogP:
1.25
PSA:
103.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
DAPORINAD
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell, Cutaneous; Melanoma
Nicotinamide phosphoribosyltransferase inhibitor
DAPORINAD
×
Maximum Phase:
2
First Approval:
None
UNII:
V71TF6V9M7
Molecule Type:
Small molecule
Molecular Formula:
C24H29N3O2
Molecular Weight:
391.52
AlogP:
3.93
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
8.0
Source:
PREDNYLIDENE
2
Small molecule
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Microscopic Polyangiitis
Unknown
PREDNYLIDENE
×
Maximum Phase:
2
First Approval:
None
UNII:
IF8PQP966U
Molecule Type:
Small molecule
Molecular Formula:
C22H28O5
Molecular Weight:
372.46
AlogP:
1.72
PSA:
94.83
HBD:
3.0
HBA:
#RotB:
2.0
Source:
TAS-106
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Head and Neck Neoplasms
DNA-directed RNA polymerase III subunit RPC1 inhibitor
TAS-106
×
Maximum Phase:
2
First Approval:
None
UNII:
Y3O05I09ZK
Molecule Type:
Small molecule
Molecular Formula:
C11H13N3O5
Molecular Weight:
267.24
AlogP:
-2.56
PSA:
130.83
HBD:
4.0
HBA:
#RotB:
2.0
Source:
VX-787
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VX-787
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-0941
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Hexokinase type IV activator
MK-0941
×
Maximum Phase:
2
First Approval:
None
UNII:
YZ1L3KR377
Molecule Type:
Small molecule
Molecular Formula:
C22H28N4O9S2
Molecular Weight:
556.62
AlogP:
2.41
PSA:
132.64
HBD:
2.0
HBA:
#RotB:
9.0
Source:
UK-500001
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase isozyme 4 inhibitor
UK-500001
×
Maximum Phase:
2
First Approval:
None
UNII:
YOG0PR3Q8J
Molecule Type:
Small molecule
Molecular Formula:
C26H24F3N3O4
Molecular Weight:
499.49
AlogP:
4.78
PSA:
100.55
HBD:
3.0
HBA:
#RotB:
6.0
Source:
RIVENPROST
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Prostanoid EP4 receptor agonist
RIVENPROST
×
Maximum Phase:
2
First Approval:
None
UNII:
1WBO45T413
Molecule Type:
Small molecule
Molecular Formula:
C24H34O6S
Molecular Weight:
450.6
AlogP:
2.94
PSA:
93.06
HBD:
2.0
HBA:
#RotB:
13.0
Source:
SODIUM CHOLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SODIUM CHOLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
NU3Y4CCH8Z
Molecule Type:
Small molecule
Molecular Formula:
C25H41NaO5
Molecular Weight:
444.59
AlogP:
3.84
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
4.0
Source:
AMINOPTERIN
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Endometrial Neoplasms; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis
Unknown
AMINOPTERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
JYB41CTM2Q
Molecule Type:
Small molecule
Molecular Formula:
C19H20N8O5
Molecular Weight:
440.42
AlogP:
0.24
PSA:
219.33
HBD:
6.0
HBA:
#RotB:
9.0
Source:
TOLIMIDONE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Tyrosine-protein kinase Lyn positive allosteric modulator
TOLIMIDONE
×
Maximum Phase:
2
First Approval:
None
UNII:
MU3JD8E9IS
Molecule Type:
Small molecule
Molecular Formula:
C11H10N2O2
Molecular Weight:
202.21
AlogP:
2.28
PSA:
55.24
HBD:
1.0
HBA:
#RotB:
2.0
Source:
552-02
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
552-02
×
Maximum Phase:
2
First Approval:
None
UNII:
81U49K9009
Molecule Type:
Small molecule
Molecular Formula:
C20H30ClN7O7S
Molecular Weight:
548.02
AlogP:
0.09
PSA:
194.99
HBD:
6.0
HBA:
#RotB:
10.0
Source:
TAK-715
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
MAP kinase p38 alpha inhibitor
TAK-715
×
Maximum Phase:
2
First Approval:
None
UNII:
WE92U03C5Z
Molecule Type:
Small molecule
Molecular Formula:
C24H21N3OS
Molecular Weight:
399.52
AlogP:
6.0
PSA:
54.88
HBD:
1.0
HBA:
#RotB:
5.0
Source:
AMITHIOZONE
2
Small molecule
Investigational
Unknown
Unknown
Mycobacterium avium-intracellulare Infection; Tuberculosis
Unknown
AMITHIOZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
MMG78X7SSR
Molecule Type:
Small molecule
Molecular Formula:
C10H12N4OS
Molecular Weight:
236.3
AlogP:
0.81
PSA:
79.51
HBD:
3.0
HBA:
#RotB:
3.0
Source:
TOVINONTRINE
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell; beta-Thalassemia
Phosphodiesterase 9A inhibitor
TOVINONTRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
W248Y1AKOR
Molecule Type:
Small molecule
Molecular Formula:
C21H26N6O2
Molecular Weight:
394.48
AlogP:
1.94
PSA:
88.41
HBD:
1.0
HBA:
#RotB:
4.0
Source:
1
2
…
106
107
108
109
110
111
112
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA